--- title: "Myriad Genetics Gains FDA Nod For Ovarian Cancer Test" type: "News" locale: "en" url: "https://longbridge.com/en/news/279512561.md" description: "Myriad Genetics, Inc. has received FDA approval for its MyChoice CDx Test as a companion diagnostic for Zejula, a PARP inhibitor for advanced ovarian cancer patients. This test identifies homologous recombination deficiency (HRD) status, crucial for treatment decisions, as nearly half of these patients have HRD-positive tumors. The MyChoice CDx Test is the only FDA-approved diagnostic for Zejula in the U.S., enhancing Myriad's role in precision medicine. MYGN stock closed at $4.78, up 4.14%, but fell to $4.70 in overnight trading." datetime: "2026-03-18T01:15:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/279512561.md) - [en](https://longbridge.com/en/news/279512561.md) - [zh-HK](https://longbridge.com/zh-HK/news/279512561.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/279512561.md) | [繁體中文](https://longbridge.com/zh-HK/news/279512561.md) # Myriad Genetics Gains FDA Nod For Ovarian Cancer Test (RTTNews) - Myriad Genetics, Inc., (MYGN) announced that the U.S. FDA has approved its MyChoice CDx Test as the companion diagnostic for Zejula, a PARP inhibitor developed by GSK, for patients with advanced ovarian cancer. The approval is based on final data from the PRIMA trial, where the MyChoice CDx Test was used to determine homologous recombination deficiency (HRD) status and stratify patients. Nearly half of women with advanced ovarian cancer have HRD-positive tumors, making accurate identification critical for guiding treatment decisions. The MyChoice CDx Test is now the only FDA-approved companion diagnostic for Zejula in the United States. It uses next-generation sequencing to assess BRCA1/2 genes- including large rearrangements- and a tumor genomic instability score that incorporates multiple markers such as loss of heterozygosity and telomeric allelic imbalance. Brian Donnelly, Chief Commercial Officer at Myriad Genetics, said the approval reinforces the company's leadership in ovarian cancer diagnostics and highlights the importance of comprehensive HRD testing. By enabling precise identification of patients who may benefit from PARP inhibitors, the test ensures treatment decisions are guided by robust genomic insights. Zejula is indicated in the U.S. for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who respond to first-line platinum-based chemotherapy and whose cancer is associated with HRD-positive status. This FDA decision marks a significant milestone for Myriad Genetics, strengthening its position in precision medicine and expanding its role in guiding personalized cancer care. MYGN has traded between $3.76 and $10.40 over the past year. The stock closed Tuesday's trading session at $4.78, up 4.14%. During overnight trading, the stock fell to $4.70, down 1.67%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [iShares Global Healthcare ETF (IXJ.US)](https://longbridge.com/en/quote/IXJ.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [Myriad Genetics, Inc. (MYGN.US)](https://longbridge.com/en/quote/MYGN.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Merck's Enlicitide Decanoate Shows Greater LDL-C Reduction Than Oral Non-Statins At 8 Weeks](https://longbridge.com/en/news/281051985.md) - [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/en/news/281026919.md) - [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/en/news/281024362.md) - [Bayer Announces Approval Of New Indication For Kerendia In The EU](https://longbridge.com/en/news/280969658.md) - [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/en/news/281015927.md)